These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17448963)

  • 21. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total body irradiation before an allogeneic stem cell transplantation: is there a magic dose?
    Adkins DR; DiPersio JF
    Curr Opin Hematol; 2008 Nov; 15(6):555-60. PubMed ID: 18832925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning.
    Zaretsky Y; Rifkind J; Lockwood G; Tsang R; Kiss T; Hasegawa W; Fyles G; Tejpar I; Loach D; Minden M; Messner H; Lipton JH
    Bone Marrow Transplant; 2007 Sep; 40(5):423-30. PubMed ID: 17603516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Height growth during adolescence and final height after haematopoietic SCT for childhood acute leukaemia: the impact of a conditioning regimen with BU or TBI.
    Bernard F; Bordigoni P; Simeoni MC; Barlogis V; Contet A; Loundou A; Thuret I; Leheup B; Chambost H; Play B; Auquier P; Michel G
    Bone Marrow Transplant; 2009 Apr; 43(8):637-42. PubMed ID: 19011662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
    Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
    Kornblit B; Masmas T; Madsen HO; Ryder LP; Svejgaard A; Jakobsen B; Sengeløv H; Olesen G; Heilmann C; Dickmeiss E; Petersen SL; Vindeløv L
    Bone Marrow Transplant; 2008 May; 41(10):851-9. PubMed ID: 18246114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
    Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
    Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
    Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
    Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there a best transplant conditioning regimen for acute myeloid leukemia?
    Appelbaum FR
    Leukemia; 2000 Mar; 14(3):497-501. PubMed ID: 10720149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of autologous transplantation for acute myeloid leukemia in first and second remission.
    Linker C
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):77-84. PubMed ID: 17336257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation.
    Rodriguez V; Kuehnle I; Heslop HE; Khan S; Krance RA
    Bone Marrow Transplant; 2002 Mar; 29(6):515-7. PubMed ID: 11960272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Re: High rate of graft failure in 25 patients with chronic myelogenous leukemia conditioned with a reduced-intensity regimen of 550 cGy total body irradiation and cyclophosphamide for unrelated donor transplantation.
    Hallemeier C
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):726-7. PubMed ID: 15389439
    [No Abstract]   [Full Text] [Related]  

  • 36. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blood and marrow transplantation in elderly acute myeloid leukaemia patients - older certainly is not better.
    Kiss TL; Sabry W; Lazarus HM; Lipton JH
    Bone Marrow Transplant; 2007 Sep; 40(5):405-16. PubMed ID: 17572706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.
    Ringdén O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin NC; Mohty M; Rocha V
    J Clin Oncol; 2009 Sep; 27(27):4570-7. PubMed ID: 19652066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.
    Yamasaki S; Heike Y; Mori S; Fukuda T; Maruyama D; Kato R; Usui E; Koido K; Kim S; Tanosaki R; Tobinai K; Teshima T; Takaue Y
    Transpl Infect Dis; 2008 Jul; 10(4):252-9. PubMed ID: 18194371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.